Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters

COVID-19 presents an ongoing global health crisis. Protein-based COVID-19 vaccines that are well-tolerated, safe, highly-protective and convenient to manufacture remain of major interest. We therefore sought to compare the immunogenicity and protective efficacy of a number of recombinant SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lei, Honda-Okubo, Yoshikazu, Baldwin, Jeremy, Bowen, Richard, Bielefeldt-Ohmann, Helle, Petrovsky, Nikolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013662/
https://www.ncbi.nlm.nih.gov/pubmed/35465982
http://dx.doi.org/10.1016/j.vaccine.2022.04.041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013662/
https://www.ncbi.nlm.nih.gov/pubmed/35465982
http://dx.doi.org/10.1016/j.vaccine.2022.04.041

Ejemplares similares